Fibrin monomer antigen: a novel marker of mortality in acute myocardial infarction
Summary
This summary is machine-generated.Elevated fibrin monomer levels predict mortality in acute myocardial infarction patients. This marker, along with age and heart failure, aids in risk stratification for better patient outcomes.
Area Of Science
- Cardiovascular Medicine
- Biomarkers
- Clinical Trials
Background
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Accurate risk stratification is crucial for managing AMI patients.
- Novel biomarkers are needed to improve prognostic assessments.
Purpose Of The Study
- To evaluate the predictive value of soluble fibrin monomer antigen for mortality in patients with acute myocardial infarction.
- To assess fibrin monomer as an independent predictor of fatal outcomes.
Main Methods
- A sensitive assay for soluble fibrin monomer antigen was employed.
- Plasma samples from 293 AMI patients in the FRAMI trial were analyzed on days 2 and 7.
- Logistic regression analysis was used to identify independent predictors of mortality.
Main Results
- Non-survivors exhibited significantly higher fibrin monomer levels compared to survivors.
- Fibrin monomer levels correlated with congestive heart failure, infarct size, and treatment modalities.
- Fibrin monomer, age, and congestive heart failure were identified as independent predictors of mortality.
Conclusions
- Increased fibrin monomer levels are a significant independent predictor of mortality in myocardial infarction.
- Fibrin monomer can enhance risk stratification when used with established factors like age and heart failure.
View abstract on PubMed